Sugi Predict

Sugi Predict / Compounds / SCHEMBL184424

SCHEMBL184424

SCHEMBL184424

CC(C)(C)OC(=O)C(N)c1cccc(C(=O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANPEP P15144 2/20 0.51
▸ ENPEP Q07075 2/20 0.51
▸ SLC7A5 Q01650 1/20 0.45
▸ PTGS1 P23219 3/20 0.40
▸ PTGS2 P35354 3/20 0.40
▸ GRM4 Q14833 1/20 0.40
▸ RXRA P19793 1/20 0.40
▸ RXRB P28702 1/20 0.40
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ AAK1 Q2M2I8 1/20 0.39
▸ AKR1C3 P42330 1/20 0.38
▸ GRM1 Q13255 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ CXCR1 P25024 2/20 0.38
▸ CXCR2 P25025 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2570186 0.85 LMNA (0.49) RXRARXRBAKR1C3SMN1; SMN2MEN1
SCHEMBL28760318 0.85 ANPEP (0.48) ANPEPENPEPSLC7A5PTGS1PTGS2
SCHEMBL30925030 0.84 PTGS1 (0.55) ANPEPENPEPPTGS1PTGS2RXRA
SCHEMBL29214270 0.84 PTGS1 (0.55) ANPEPENPEPPTGS1PTGS2RXRA
SCHEMBL27927308 0.83 ANPEP (0.47) ANPEPENPEPSLC7A5PTGS1PTGS2
SCHEMBL305032 0.82 L3MBTL1 (0.45) SLC7A5AAK1MAPTSMN1; SMN2MEN1
SCHEMBL30065221 0.82 L3MBTL1 (0.45) SLC7A5AAK1MAPTSMN1; SMN2MEN1
SCHEMBL594359 0.82 L3MBTL1 (0.45) SLC7A5AAK1MAPTSMN1; SMN2MEN1
SCHEMBL7210714 0.82 CPN1 (0.42) SLC7A5CA1CA2CA9KMT2A
SCHEMBL8909021 0.82 ADRB1 (0.46) SLC7A5KDM4ELMNACYP3A4HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108472381-B Compounds and therapeutic uses thereof 森陶里治疗有限公司 2023-06-06 — — CN disclosed
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2021-12-02 — — US disclosed
US-10953100-B2 Compounds and therapeutic uses thereof CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2021-03-23 — — US disclosed
US-20210079444-A1 LABEL FREE DETECTION OF PROTEASE ACTIVITY VIB VZW (BE) 2021-03-18 — — US disclosed
EP-3645453-A1 LABEL FREE DETECTION OF PROTEASE ACTIVITY Universiteit Gent (BE) 2020-05-06 — — EP disclosed
WO-2019002401-A1 LABEL FREE DETECTION OF PROTEASE ACTIVITY VIB VZW (BE) 2019-01-03 — — WO disclosed
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2018-10-04 — — US disclosed
EP-3012254-B1 BIPHENYL DERIVATIVE AND ITS USE FOR TREATING PULMONARY DISORDERS THERAVANCE RESPIRATORY CO LLC (US) 2017-05-17 — — EP disclosed
WO-2017060729-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTAURI THERAPEUTICS LIMITED (GB) 2017-04-13 — — WO disclosed
EP-3012254-A1 BIPHENYL DERIVATIVE AND ITS USE FOR TREATING PULMONARY DISORDERS Theravance Respiratory Company, LLC (US) 2016-04-27 — — EP disclosed
WO-1999040083-A2 BIFUNCTIONAL TRYPTASE INHIBITORS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1999-08-12 — — WO disclosed
US-5922770-A NOVEL COMPOUNDS THAT STIMULATE THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 1999-07-13 — — US disclosed
EP-0923539-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-06-23 — — EP disclosed
CN-1211991-A Compounds with growth hormone releasing properties NOVO NORDISK AS (DK) 1999-03-24 — — CN disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed
CN-1176645-A Compounds with growth hormone releasing properties NOVO NORDISK AS (DK) 1998-03-18 — — CN disclosed
WO-1998003473-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-01-29 — — WO disclosed
EP-0805816-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-11-12 — — EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 — — WO disclosed
WO-1996022997-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1996-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 ANPEP 2972/4885ENPEP 414/4885SLC7A5 4151/4885
US-10953100-B2 Compounds and therapeutic uses thereof CD47, MYD88, NFATC1 ANPEP 2972/4885ENPEP 414/4885SLC7A5 4151/4885
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 ANPEP 2972/4885ENPEP 414/4885SLC7A5 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.